

Tumor Signal Transduction - Liquid Biopsy Detecting cancer therapy resistance in real-time

Ming-Chung Jiang

National Taiwan University, Taiwan

ABSTRACT

Breast cancer is a very important problem for women in the world, where cancer prevalence is gradually increasing. Breast cancer accounts for 23% of all cancer cases and 14% of deaths due to cancer among women.(1) Many advances in cancer diagnosis and treatment have, of course, reflected on breast cancer. In fact, it would not be wrong to say that breast cancer is one of the pioneers of this development. The chance of success in treating breast cancer is directly related to how early the cancer is caught. When detected at an early stage, the 5-year survival rate can reach 96 percent. Breast cancer treatment is done according to the stage of breast cancer and the current health status of the patient.(2)Although the priority in the treatment is the protection of the breast tissue, the breast tissue can be completely removed with the mastectomy procedure when necessary. After surgery, radiotherapy and chemotherapy may be required.(3) In studies, the preliminary results of which have been recently reported, biological agent combinations, including trastuzumab, will have an important place among the treatment strategies that will be determined according to the molecular properties of tumors in the future.(4) In parallel with the development of nanotechnological methods, reconstructing or newly discovered drugs can be applied like a guided missile, targeting only cancer cells, without damaging living cells, will be a very important step in cancer treatment strategies in the near future. (5). Our longer-term goal is to map each cancer separately and to treat it with the cancer-specific treatment method that each patient carries. In this way, it will be possible for each patient to create a three-dimensional information technology network that includes the genetic characteristics of cancer, the prevalence of the disease in the body, its stage and treatment features. If we can take this one step further, thanks to the international information sharing, it will be possible for each patient to have the opportunity to easily access special treatments for him / her, no matter where they are, together with their physician.

Biography

Ming-Chung Jiang: CEO of Targetrust Biotech. Ltd. He has obtained a PHD in Biochemistry from the College of Medicine,

National Taiwan University. He has Patents Granted: USA, China, Taiwan, Japan, Canada, Indonesia, and India. Pending: EPC.

Citation: Huang Wei Ling; Ming-Chung Jiang: Tumor Signal Transduction - Liquid Biopsy Detecting cancer therapy resistance in real-time, Cancer 2021, May 25, 2021, London, UK.

Copyright: © 2021. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.